AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15030985 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a plus ribavirin
Number of subjects: 1121
Study 15030985 — intervention group
Group type: COMPARATOR
Intervention: peginterferon alfa‐2a plus placebo
Number of subjects: 1121
Study 15030985 — intervention group
Group type: COMPARATOR
Intervention: interferon alfa‐2b plus ribavirin
Number of subjects: 1121
Study 15030985 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained virological response
Number of subjects: 1121
Study 12860733 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year
Number of subjects: 146
Study 12860733 — intervention group
Group type: COMPARATOR
Intervention: Single disease modifying antirheumatic drug treatment
Number of subjects: 146
Study 10073394 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants
Number of subjects: 0
Study 10073394 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 0
Study 8541274 — intervention group
Group type: EXPERIMENTAL
Intervention: Locust-bean (Ceratonia siliqua) gum
Number of subjects: 0
Study 8541274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre from lupin (Lupinus albus) and insoluble maize-cob fibre
Number of subjects: 0
Study 8541274 — intervention group
Group type: EXPERIMENTAL
Intervention: Locust-bean gum
Number of subjects: 0
Study 1742915 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP vaccine
Number of subjects: 101
Study 1742915 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 101
Study 7096149 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at 60% VO2 max
Number of subjects: 6
Study 7096149 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at 80% VO2 max
Number of subjects: 6
Study 7096149 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min treadmill run at self-selected pace
Number of subjects: 6
Study 7096149 — intervention group
Group type: COMPARATOR
Intervention: 30 min rest (control experiment)
Number of subjects: 6
Study 30123586 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of quadriceps (QG, n=24)
Number of subjects: 67
Study 30123586 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=26)
Number of subjects: 67
Study 30123586 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation of diaphragm (DG, n=17)
Number of subjects: 67
Study 26857391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultramicronized Palmitoylethanolamide (um-PEA) added to IFN-β1a
Number of subjects: 0
Study 26857391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24612546 — intervention group
Group type: EXPERIMENTAL
Intervention: AST1306 at 1000 mg BID
Number of subjects: 71
Study 24612546 — intervention group
Group type: EXPERIMENTAL
Intervention: AST1306 at 1500 mg BID
Number of subjects: 71
Study 24612546 — intervention group
Group type: EXPERIMENTAL
Intervention: AST1306 at 800 mg TID
Number of subjects: 71
Study 24612546 — intervention group
Group type: EXPERIMENTAL
Intervention: AST1306 at 1200 mg TID
Number of subjects: 71
Study 24612546 — intervention group
Group type: EXPERIMENTAL
Intervention: AST1306 (various doses)
Number of subjects: 71
Study 24612546 — intervention group
Group type: EXPERIMENTAL
Intervention: AST1306 under fed conditions
Number of subjects: 71
Study 23271159 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS Turkey intervention group (text messaging-based smoking cessation program)
Number of subjects: 151
Study 23271159 — intervention group
Group type: COMPARATOR
Intervention: Brochure control group
Number of subjects: 151
Study 23271159 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS Turkey intervention group (female participants)
Number of subjects: 151
Study 23271159 — intervention group
Group type: COMPARATOR
Intervention: Brochure control group (female participants)
Number of subjects: 151
Study 23271159 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS Turkey intervention group (light smokers)
Number of subjects: 151
Study 23271159 — intervention group
Group type: COMPARATOR
Intervention: Brochure control group (light smokers)
Number of subjects: 151
Study 19880790 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (40, 80, or 120 microg/kg, administered sc, twice daily)
Number of subjects: 136
Study 19880790 — intervention group
Group type: COMPARATOR
Intervention: Control group (observed, n = 25)
Number of subjects: 136
Study 19880790 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I (120 microg/kg)
Number of subjects: 136
Study 19880790 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I treatment
Number of subjects: 136
Study 17390422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 15
Study 17390422 — intervention group
Group type: COMPARATOR
Intervention: Dyclonine
Number of subjects: 15
Study 17390422 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 15
Study 15604947 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ROI techniques
Number of subjects: 20
Study 15604947 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automatic ROI techniques
Number of subjects: 20
Study 15604947 — intervention group
Group type: COMPARATOR
Intervention: Mirror technique
Number of subjects: 20
Study 15604947 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of fractional change during treatment
Number of subjects: 20
Study 15604947 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion of quantitative methods to measure fractional change
Number of subjects: 20
Study 12020483 — intervention group
Group type: EXPERIMENTAL
Intervention: PTMR plus maximal medical therapy (MMT)
Number of subjects: 141
Study 12020483 — intervention group
Group type: COMPARATOR
Intervention: MMT only
Number of subjects: 141
Study 12020483 — intervention group
Group type: EXPERIMENTAL
Intervention: PTMR plus MMT
Number of subjects: 141
Study 9665202 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) maintenance treatment at a starting dose of 3 mU/m2 three times per week.
Number of subjects: 92
Study 9665202 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 92
Study 9665202 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN) maintenance treatment.
Number of subjects: 92
Study 9665202 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha (IFN) maintenance treatment and No treatment (control group).
Number of subjects: 92
Study 7864608 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% fructose with 3% soluble fibre and 1% insoluble fibre preload
Number of subjects: 24
Study 7864608 — intervention group
Group type: EXPERIMENTAL
Intervention: Preload (any type)
Number of subjects: 24
Study 7864608 — intervention group
Group type: COMPARATOR
Intervention: Fructose/fibre or placebo
Number of subjects: 24
Study 2681410 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine conventional (5 mg twice a day)
Number of subjects: 19
Study 2681410 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine extended release (10 mg once daily)
Number of subjects: 19
Study 2681410 — intervention group
Group type: COMPARATOR
Intervention: Felodipine conventional and extended release
Number of subjects: 19
Study 4479277 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume feeds (230 ml/kg/day of S.M.A. S26 milk)
Number of subjects: 5
Study 4479277 — intervention group
Group type: COMPARATOR
Intervention: Conventional feeds (180 ml/kg/day of S.M.A. S26 milk)
Number of subjects: 5
Study 31860387 — intervention group
Group type: EXPERIMENTAL
Intervention: PQQ (20 mg/day)
Number of subjects: 23
Study 31860387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 23
Study 31860387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PQQ and PLC)
Number of subjects: 23
Study 30844949 — intervention group
Group type: COMPARATOR
Intervention: PEEPARDSNET (13 ± 1 cm H2O)
Number of subjects: 14
Study 30844949 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPINCREMENTAL (22 ± 3 cm H2O)
Number of subjects: 14
Study 30844949 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEPDECREMENTAL (21 ± 4 cm H2O)
Number of subjects: 14
Study 29234749 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% autogenous bone mixed with 50% anorganic bovine bone (group A)
Number of subjects: 32
Study 29234749 — intervention group
Group type: COMPARATOR
Intervention: 100% anorganic bovine bone (group B)
Number of subjects: 32
Study 26790796 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular mixture of drugs (bupivacaine, ketorolac, morphine, adrenaline)
Number of subjects: 80
Study 26790796 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 80
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: CANSAS-C (Clinician-rated)
Number of subjects: 605
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: CANSAS-P (Patient-rated)
Number of subjects: 605
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-C (Clinician-rated)
Number of subjects: 605
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS-P (Patient-rated)
Number of subjects: 605
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: CANSAS and HAS-C
Number of subjects: 605
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: CANSAS
Number of subjects: 605
Study 23452753 — intervention group
Group type: EXPERIMENTAL
Intervention: HAS
Number of subjects: 605
Study 21547879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Phosphate (NaP)
Number of subjects: 634
Study 21547879 — intervention group
Group type: EXPERIMENTAL
Intervention: colonLYTLEY (PEG)
Number of subjects: 634
Study 21547879 — intervention group
Group type: EXPERIMENTAL
Intervention: Picoprep (Pico)
Number of subjects: 634
Study 18675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative investigator-initiated clinical research in critical care
Number of subjects: 0
Study 18675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised-controlled trials
Number of subjects: 0
Study 18675179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing collaboration between research groups
Number of subjects: 0
Study 17245476 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blockers
Number of subjects: 0
Study 17245476 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (e.g., pioglitazone)
Number of subjects: 0
Study 14512874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV) monotherapy
Number of subjects: 5
Study 14512874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Number of subjects: 5
Study 14512874 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (IFN-alpha) monotherapy
Number of subjects: 5
Study 14512874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 10710050 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 32
Study 10436945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilestrioli 2 mg twice a month and Perphenazine 12 mg and Doxepin 75 mg per day
Number of subjects: 80
Study 10436945 — intervention group
Group type: COMPARATOR
Intervention: Tolfenamic acid 300 mg a day
Number of subjects: 80
Study 7955699 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Keller-Lelievre operation
Number of subjects: 35
Study 7955699 — intervention group
Group type: COMPARATOR
Intervention: Original Keller-Lelievre technique
Number of subjects: 35
Study 2956874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enoximone (150 mg 3 times daily)
Number of subjects: 17
Study 2956874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2956874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enoximone (0.75 mg/kg)
Number of subjects: 17
Study 31396995 — intervention group
Group type: EXPERIMENTAL
Intervention: PBK-1701TC (320 mg simethicone)
Number of subjects: 224
Study 31396995 — intervention group
Group type: COMPARATOR
Intervention: Oral sulfate solution (OSS)
Number of subjects: 224
Study 31396995 — intervention group
Group type: EXPERIMENTAL
Intervention: PBK-1701TC
Number of subjects: 224
Study 28743135 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical treatment
Number of subjects: 21
Study 28743135 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 21
Study 29262825 — intervention group
Group type: EXPERIMENTAL
Intervention: CCOT (Curcuminoids extract, hydrolyzed collagen and green tea extract)
Number of subjects: 42
Study 29262825 — intervention group
Group type: COMPARATOR
Intervention: Control (experimental diet without CCOT)
Number of subjects: 42
Study 29262825 — intervention group
Group type: EXPERIMENTAL
Intervention: CCOT
Number of subjects: 42
Study 29262825 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 26418341 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg twice-daily plus Vitamin D3 1,000 IU twice-daily
Number of subjects: 57
Study 26418341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 23801725 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-saturated-fat dietary counseling
Number of subjects: 518
Study 23801725 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 518
Study 21669891 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized care group with brief physician training and computer-assisted medication management
Number of subjects: 24
Study 21669891 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 24
Study 18952455 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 141
Study 18952455 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 141
Study 16776387 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to automated patient registries and semi-automated clinical measure reports; five sites received computerized clinical reminders; three one-day learning sessions conducted.
Number of subjects: 9
Study 16776387 — intervention group
Group type: EXPERIMENTAL
Intervention: Three one-day learning sessions conducted.
Number of subjects: 9
Study 16776387 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened learning sessions and incorporation of health information technology.
Number of subjects: 9
Study 16776387 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per site.
Number of subjects: 9
Study 15312348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vp‐16 1000 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Number of subjects: 30
Study 15312348 — intervention group
Group type: EXPERIMENTAL
Intervention: Vp‐16 1500 mg/m(2) with rhG‐CSF 300 microg.body(‐1).day(‐1)
Number of subjects: 30
Study 15312348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison group receiving different Vp‐16 dosage)
Number of subjects: 30
Study 11514693 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulised salbutamol
Number of subjects: 20
Study 11514693 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg nebulised ipratropium bromide
Number of subjects: 20
Study 11514693 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salbutamol and ipratropium
Number of subjects: 20
Study 11514693 — intervention group
Group type: COMPARATOR
Intervention: Nebulised saline
Number of subjects: 20
Study 9297994 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily and hydrochlorothiazide 12.5-25.0 mg daily)
Number of subjects: 4695
Study 9297994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study 7904411 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliotherapy for 4 weeks
Number of subjects: 95
Study 3556957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg every 6 h intravenously and colloidal aluminium phosphate 11 g every 4 h per os
Number of subjects: 31
Study 3556957 — intervention group
Group type: COMPARATOR
Intervention: No preventive treatment
Number of subjects: 31
Study 30322408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab plus methotrexate
Number of subjects: 60
Study 30322408 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 60
Study 30322408 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 60
Study 30322408 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients who never achieved drug-free status)
Number of subjects: 60
Study 26420761 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) infusion
Number of subjects: 20
Study 26420761 — intervention group
Group type: COMPARATOR
Intervention: Standard anaesthetic treatment (Control)
Number of subjects: 20
Study 25192393 — intervention group
Group type: EXPERIMENTAL
Intervention: Argentine tango (AT) class, 1 hour twice weekly for 2 years
Number of subjects: 10
Study 25192393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prescribed exercise)
Number of subjects: 10
Study 22866433 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside nurse-to-nurse handoff
Number of subjects: 60
Study 20426834 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 140
Study 20426834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 18979878 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryan cervical disc arthroplasty (group A)
Number of subjects: 52
Study 18979878 — intervention group
Group type: COMPARATOR
Intervention: Traditional anterior cervical discectomy and fusion (group B)
Number of subjects: 52
Study 15868884 — intervention group
Group type: COMPARATOR
Intervention: Linoleic acid diet
Number of subjects: 0
Study 15868884 — intervention group
Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 0
Study 12848633 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 10 or 20 mg once daily for 4 weeks
Number of subjects: 826
Study 12848633 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 826
Study 10827369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafiban (up to 50 mg twice daily)
Number of subjects: 9200
Study 10827369 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (standard therapy)
Number of subjects: 9200
Study 8890722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 25 micrograms
Number of subjects: 0
Study 8890722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 50 micrograms
Number of subjects: 0
Study 8890722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 100 micrograms
Number of subjects: 0
Study 8890722 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine 150 micrograms
Number of subjects: 0
Study 8890722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thyroxine administration)
Number of subjects: 0
Study 8448808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (ionic contrast agent)
Number of subjects: 500
Study 8448808 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (nonionic contrast agent)
Number of subjects: 500
Study 8448808 — intervention group
Group type: COMPARATOR
Intervention: Nonionic agent (iohexol)
Number of subjects: 500
Study 3519243 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 75 mg/day
Number of subjects: 0
Study 3519243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination tablet containing 5 mg amiloride and 50 mg hydrochlorothiazide (Moduretic)
Number of subjects: 0
Study 3519243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 15 mg/day added to hydrochlorothiazide
Number of subjects: 0
Study 3519243 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride reduced to 7.5 mg/day using Moduretic
Number of subjects: 0
Study 31062629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 133
Study 31062629 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 133
Study 30184553 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 880
Study 30184553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study 26387640 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical trainer
Number of subjects: 12
Study 26387640 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill workstation
Number of subjects: 12
Study 26387640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic workstations (elliptical trainer and treadmill)
Number of subjects: 12
Study 26387640 — intervention group
Group type: COMPARATOR
Intervention: Conventional sitting and standing workstations
Number of subjects: 12
Study 25566573 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical suspension formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Number of subjects: 20
Study 25566573 — intervention group
Group type: COMPARATOR
Intervention: Ointment formulation of calcipotriene 0.005%‐betamethasone dipropionate 0.064%
Number of subjects: 20
Study 25566573 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical suspension formulation
Number of subjects: 20
Study 22835597 — intervention group
Group type: COMPARATOR
Intervention: Control (0% DHA)
Number of subjects: 141
Study 22835597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32% DHA
Number of subjects: 141
Study 22835597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.96% DHA
Number of subjects: 141
Study 22835597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.64% DHA
Number of subjects: 141
Study 21054830 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored information related to social-cognitive determinants of screening (Group B)
Number of subjects: 10000
Study 21054830 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored information addressing cultural factors related to screening (Group C)
Number of subjects: 10000
Study 21054830 — intervention group
Group type: COMPARATOR
Intervention: Generic information on HBV (Group A)
Number of subjects: 10000
Study 18702951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 or 30 mg/d for 6 months)
Number of subjects: 27
Study 18702951 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500 or 750 mg/d for 6 months)
Number of subjects: 27